Key facts
- Adyn’s last known valuation is $2.1M (Aug 2020).
- It has raised $2.6M; the latest was Later Stage VC in Nov 2025.
- Notable investors include Y Combinator, Pioneer Fund, Lux Capital, Makai VC, Madrona Venture Group — 17 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 17 names
- ·Watchlist + deal alerts for Adyn
- ·The full record, as it builds
Funding rounds
No funding rounds for Adyn are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Adyn
Developer of a birth control optimization test designed to help determine an appropriate method of birth control, minimizing the likelihood of unwanted side effects. The company offers an at-home hormone and genetic sampling kit, combined with medical profile analysis and licensed provider review, enabling women seeking birth control or family-planning support to have more informed and personalized reproductive health care.
- Sector
- Healthcare
- HQ
- Claymont, DE, United States
- Founded
- 2019
- Employees
- 9
- Website
- adyn.com/
- Ownership
- Privately Held (backing)
Adyn doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Adyn shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Adyn in its N-PORT filings yet. We sweep new filings monthly.